SHANGHAI, June 19, 2023, 13:00-17:00 CST. The 4th "Health & Pharma Partner" Innovation and BD Partnership" Forum jointly organized by Shanghai SinoExpo, China Chamber of Commerce for Import & Export of Medicine and Health Products (CCCMHPIE), and Angine Bio. Co., Ltd. was successfully held during 2023 CPhI Shanghai. The theme is "Innovation and Internationalization Development of Chinese pharmaceutical Companies in the New Era - Models, Challenges and Opportunities", and 6 well-known experts in the industry share the insight for the topic. And the speakers are Mr. Leo Luo, founding partner of "Health & Pharma Partner” Innovation Center and AngineBio. Co., Ltd.; Mr. Kapil Gupta, Head of BD Partnership, Zenvision Pharmaceuticals, India; Dr. Xiaofeng Meng /MBA, Chairman and CEO of Epic Pharma; Dr. Jia Huijuan, Founder and CEO of Ruichuang Kangtai Medicine; Dr. Shao Ke, Deputy General Manager of Kexing Biopharmaceutical Co., Ltd.
Highlights of the Presentation
In a rapidly evolving business landscape with an increasingly interconnected and dynamic global market requirements, where growth and innovation are essential for success of an organization, Business Development (BD) and Alliance Management, plays a pivotal role in shaping the success of organizations across industries and fosters international expansion and access.
The internationalization model of Chinese pharmaceutical companies should be transformed and upgraded, and the transformation and upgrading of international business from international trade to international BD should be aware of.
API still account for the majority share of China's pharmaceutical exports (more than 80% of total exports). Europe, America and India are still the mainstream markets for pharmaceuticals' export from China, and the potential of Southeast Asia and "the Belt and Road"makets needs to be continuously explored . Innovative drugs/APIs/Excipients/packaging materials are still the main categories of imports.
As for internal internationalization capabilities, China Pharma companies need to enforce its own capabilities by the more devotion to the innovation as well as more deep understanding for the global market regulations.
The 505 (b) (2) project is both a challenge and an opportunity, and the clinical value as well as the academic outreach to the KOL remain the core competencies. The US market remains one of the largest international markets for the 505 (b) (2) program, with a high acceptance of generic drugs and the highest generic drug sales in the world, accounting for about 28% of global generic drug sales in 2020, so competition is also fierce. Chinese pharmaceutical companies should make good use of their own advantages, while paying close attention to the United States drug shortage, familiar with the FDA regulations, in order to stand in the crowded pharmaceutical market.
In the face of increasing domestic competition, pharmaceutical companies are also undergoing the commercialization transformation. Therefore, for innovative drugs, "license-out" and internationalization are the core of commercial success. In the process of internationalization, pharmaceutical companies should select the appropriate target markets, expand the cooperation dimension with the deep understanding for the local market access regulations, and build the deep relationship with the local partners so as to achieve the win-win partnership.
In the coming months, Angine will continue to hold the relevant international and BD cooperation and innovation development forums together with the academic and industry strategic partners.
For more information about China market access regulation, China innovation as well as the BD partnership opportunities, you can visit https://www.angineglobal.com/#/ to have more insightful information.
About Angine
Angine is a international business development solution provider company dedicated in the pharma, biotech and medical device fields for the global business partnership building. We are working with our overseas' business partner to introduce the clinical and market unmet projects/products to China by leveraging the local expertise and resources as well as “license-out” the innovative pipeline products from China to overseas partners.
With the professional international BD team, the expert consultant group as well as the valuable data room for Chinese markets in the biotech and health care field, Angine is committed to provide the tailor-made solutions for our overseas clients who would like to explore the access to the Chinese market as well as build the win-win partnership with “same-minded”Chinese partner. The solutions are including but not limited to the strategic biz partnership building and right partnership model defining, Chinese market landscape investigation, the regulatory affairs support, the reimbursement policy study, and the ideal incubator & industry park recommendation as well as the capital and talent services supporting.
Angine would like work with you as a strategic partner to co-develop the Chinese healthcare market, to make your ideas, IP become the products by inputting the expertise from both sides and make your products launched in China by the solutions from Angine.
You can write an email to bd@anginebio.com for your ideas and proposals for the Chinese markets. Let our team give you a solution.